Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Price Target from Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA) has received an average rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $23.00.

A number of research analysts have recently issued reports on AURA shares. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday. Scotiabank lifted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. Finally, BTIG Research increased their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th.

Aura Biosciences Price Performance

NASDAQ:AURA opened at $7.85 on Friday. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38. The company has a 50-day moving average of $8.28 and a 200 day moving average of $8.90. The firm has a market cap of $392.11 million, a PE ratio of -4.54 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. Sell-side analysts anticipate that Aura Biosciences will post -1.66 EPS for the current fiscal year.

Insider Activity

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the sale, the insider now directly owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. This represents a 7.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,778 shares of company stock worth $240,706 over the last 90 days. 5.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of large investors have recently bought and sold shares of AURA. American Century Companies Inc. purchased a new position in Aura Biosciences during the 2nd quarter worth approximately $119,000. Dimensional Fund Advisors LP raised its holdings in shares of Aura Biosciences by 20.0% during the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Aura Biosciences by 26.3% during the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after purchasing an additional 15,000 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Aura Biosciences by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after purchasing an additional 8,194 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Aura Biosciences in the third quarter valued at $169,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.